Press Release

Immunoglobulins Market Development, Key Opportunity, Application and Forecast to 2025

Immunoglobulins Market Robust Expansion by Top Key Manufactures | Worldwide Overview by Size, Share, Trends, Segments

Rising at a CAGR of 7.0% between 2018 and 2025, the global immunoglobulins market is forecast to remain strong through the forecast period. Fortune Business Insights in a report, titled “Immunoglobulins: Global Market Analysis, Insights and Forecast, 2018-2025” states that the global market was worth US$ 10,750.0 Mn in 2017. The market is further expected to reach US$ 18,378.0 Mn by the end of 2025.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunoglobulins-market-100571

Leading Players operating in the Immunoglobulin Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • CSL Behring
  • Grifols, S.A.
  • Kedrion S.p.A
  • Octapharma
  • Bio Products Laboratory Ltd.
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • LFB SA and Shanghai RAAS Blood Products Co., Ltd.

Upgrade in Intervention Technology to Propel Growth

The increasing cases of chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI) are the major factors anticipated to drive the global immunoglobulins market. Furthermore, technological upgrades in the administration methods are likely to fuel the demand for immunoglobulins test and structure.

CUVITRU, a subcutaneous immunoglobulin introduced by Shire to facilitate the treatment of primary immunodeficiency, is the only 20% subcutaneous immunoglobulin in the U.S. without proline. Such launches are likely to enable growth in the global immunoglobulins market.

However, high costs associated with immunoglobulins and side-effects associated with immunoglobulins are a few key factors that may restrain the market.

In terms of region, North America is foreseen to emerge dominant over the forecast period. The region also held a major share in the market in 2017. The North America immunoglobulins market was worth US$ 6,291.5 Mn in 2017. Immunoglobulin is the most popular treatment available for various immune disorders. Moreover, the number of patients in the region is increasing. These factors are anticipated to contribute towards market growth.

Detailed Table of Content:

  1. Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  4. Key Insights
    • Pipeline Analysis
    • Overview of Regulatory Scenario by Key Regions
    • Key Industry Developments
    • Number of Primary Immunodeficiency (PI) Patients by Key Countries
    • Overview of Reimbursement Scenario
  5. Global Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Route of Administration
      • Intravenous (IV)
      • Subcutaneous (SC)
    • Market Analysis, Insights and Forecast – By Indication
      • Primary Immunodeficiency
      • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • Guillain-Barré Syndrome (GBS)
      • Immune Thrombocytopenic Purpura (ITP)
      • Multifocal Motor Neuropathy (MMN)
      • Others
    • Market Analysis, Insights and Forecast – By Form
      • Liquid
      • Lyophilized
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Clinics
      • Homecare
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia Pacific
      • Latin America
      • Middle East & Africa
  1. North America Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis – By Route of Administration
      • Intravenous (IV)
      • Subcutaneous (SC)
    • Market Analysis – By Indication
      • Primary Immunodeficiency
      • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • Guillain-Barré Syndrome (GBS)
      • Immune Thrombocytopenic Purpura (ITP)
      • Multifocal Motor Neuropathy (MMN)
      • Others
    • Market Analysis – By Form
      • Liquid
      • Lyophilized
    • Market Analysis – By End User
      • Hospitals
      • Clinics
      • Homecare
    • Market Analysis – By Country
      • S.
      • Canada
  1. Europe Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis – By Route of Administration
      • Intravenous (IV)
      • Subcutaneous (SC)
    • Market Analysis – By Indication
      • Primary Immunodeficiency
      • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • Guillain-Barré Syndrome (GBS)
      • Immune Thrombocytopenic Purpura (ITP)
      • Multifocal Motor Neuropathy (MMN)
      • Others
    • Market Analysis – By Form
      • Liquid
      • Lyophilized
    • Market Analysis – By End User
      • Hospitals
      • Clinics
      • Homecare
    • Market Analysis – By Country/ Sub-Region
      • K.
      • Germany
      • France
      • Spain
      • Italy
      • Scandinavia
      • Rest of Europe
  1. Asia Pacific Immunoglobulins Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis – By Route of Administration
      • Intravenous (IV)
      • Subcutaneous (SC)
    • Market Analysis – By Indication
      • Primary Immunodeficiency
      • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
      • Guillain-Barré Syndrome (GBS)
      • Immune Thrombocytopenic Purpura (ITP)
      • Multifocal Motor Neuropathy (MMN)
      • Others
    • Market Analysis – By Form
      • Liquid
      • Lyophilized
    • Market Analysis – By End User
      • Hospitals
      • Clinics
      • Homecare
    • Market Analysis – By Country/ Sub-Region
      • Japan
      • China
      • India
      • Australia
      • Southeast Asia
      • Rest of Asia Pacific

Continued…

Market Segmentation:

By Route of Administration

  • Intravenous (IV)
  • Subcutaneous (SC)

By Indication

  • Primary Immunodeficiency
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Guillain-Barré Syndrome (GBS)
  • Immune Thrombocytopenic Purpura (ITP)
  • Multifocal Motor Neuropathy (MMN)
  • Others

By Form

  • Liquid
  • Lyophilized

By End User

  • Hospitals
  • Clinics
  • Homecare

By Geography

  • North America (the U.S., and Canada)
  • Europe (Germany, U.K., France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (China, India, Japan, Australia, South East Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America
  • Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa)

 

Tags
Show More

Betti Stone

Hi, let me cordially welcome you to medical market news. I am Bettie, the chief editor of the website. I have gathered years of experiencing in this website and not only experience but also memories. I have to manage the dynamic editorial team and oversee all strategy and content initiatives. Though I love my job a lot sometimes, I even enjoy the fresh air outside and hence take a walk during a break and re-energise myself.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close